← Abivax SA overview

Abivax SA vs Eurofins Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Abivax SA (ABVX.PA)

Q2 2026
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

June 2026
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

Latest
▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

  • Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.

    This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.

  • Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.

    This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.

  • Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.

    This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.

  • Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.

    This is a negative factor that could pressure the stock, providing a balanced view of risks.

Eurofins Scientific SE (ERF.PA)

Q3 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

August 2026
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.

Latest
▲4

Eurofins sharpens focus on life sciences with buybacks and deals

  • Strong first-half results and record cash conversion Eurofins reported 29% earnings-per-share growth, a record 47% cash conversion and EUR 200 million of share buybacks in the first half. Stronger profits and cash give the company more room to invest and return money to shareholders, which supports the shares.

    This is the period's core company result and the main fundamental driver of the stock.

  • Ongoing share buybacks support the stock Eurofins kept buying back its own shares through July and August, repurchasing 85,000 shares one week and 100,000 the next. Buybacks reduce the number of shares in circulation and signal management confidence, which tends to support the share price.

    Buybacks are a repeated but still active capital-return signal that helps explain price support.

  • Portfolio reshaped toward core life sciences testing Eurofins completed the EUR 575 million sale of its MET Labs electrical testing unit and the USD 400 million purchase of Element's North American life sciences business. It is swapping a non-core asset for 27 labs and over USD 150 million of annual revenue in a region where it was underrepresented.

    These two completed deals are the period's biggest strategic moves and directly affect future growth and capital allocation.

  • Growing market for preclinical cell-based testing A new report forecasts the preclinical cell-based assay services market to grow from about USD 4.5 billion in 2025 to USD 12.9 billion by 2035, with Eurofins named among the leading providers. A larger market gives Eurofins more room to win new testing work.

    This is the period's main demand-side signal for Eurofins' core testing business.